|
Report Date : |
05.01.2013 |
IDENTIFICATION DETAILS
|
Name : |
BOEHRINGER
INGELHEIM AB |
|
|
|
|
Registered Office : |
Liljeholmsstranden
3 PO Box 47608 Stockholm, SE 117 94 |
|
|
|
|
Country : |
Sweden |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Year of Incorporation : |
1965 |
|
|
|
|
Com. Reg. No.: |
5561030650 |
|
|
|
|
Legal Form : |
Private Subsidiary |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
100 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2011) |
Current Rating (30.06.2012) |
|
Sweden |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SWEDEN - ECONOMIC OVERVIEW
Aided by peace and neutrality for the whole of the 20th
century, Sweden has achieved an enviable standard of living under a mixed
system of high-tech capitalism and extensive welfare benefits. It has a modern
distribution system, excellent internal and external communications, and a
highly skilled labor force. In September 2003, Swedish voters turned down entry
into the euro system concerned about the impact on the economy and sovereignty.
Timber, hydropower, and iron ore constitute the resource base of an economy
heavily oriented toward foreign trade. Privately owned firms account for vast
majority of industrial output, of which the engineering sector accounts for
about 50% of output and exports. Agriculture accounts for little more than 1%
of GDP and of employment. Until 2008, Sweden was in the midst of a sustained
economic upswing, boosted by increased domestic demand and strong exports. This
and robust finances offered the center-right government considerable scope to
implement its reform program aimed at increasing employment, reducing welfare
dependence, and streamlining the state's role in the economy. Despite strong
finances and underlying fundamentals, the Swedish economy slid into recession
in the third quarter of 2008 and growth continued downward in 2009 as
deteriorating global conditions reduced export demand and consumption. Strong
exports of commodities and a return to profitability by Sweden's banking sector
drove the strong rebound in 2010, which continued in 2011, and the government
is proposing stimulus measures in the 2012 budget to curb the effects of a
global economic slowdown and boost employment and growth.
Source
: CIA
Boehringer Ingelheim AB
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Business Description
|
Boehringer Ingelheim AB is primarily engaged
in manufacturing vaccines, toxoids, blood fractions, and culture media of
plant or animal origin (except diagnostic). |
Industry
|
Industry |
|
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal Product
Manufacturing |
|
NACE 2002: |
|
|
NAICS 2002: |
|
|
UK SIC 2003: |
|
|
UK SIC 2007: |
|
|
US SIC 1987: |
|
|
|
|
Key Executives
|
1 - Profit & Loss Item Exchange Rate: USD 1 = SEK 6.49369
2 - Balance Sheet Item Exchange Rate: USD 1 = SEK 6.8553
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Boehringer Ingelheim AB |
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
Parent |
Ingelheim Am Rhein |
Germany |
Food Processing |
20,200.5 |
120 |
|
|
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Biotechnology and Drugs |
18,313.7 |
44,094 |
|
|
Subsidiary |
Columbus, OH |
United States |
Biotechnology and Drugs |
223.7 |
1,000 |
|
|
Branch |
Columbus, OH |
United States |
Biotechnology and Drugs |
|
4 |
|
|
Subsidiary |
Dublin |
Ireland |
Personal and Household Products |
12.1 |
892 |
|
|
Subsidiary |
Petersburg, VA |
United States |
Chemical Manufacturing |
|
375 |
|
|
Boehringer Ingelheim International Trading
(Shanghai) Co., Ltd. |
Subsidiary |
Shanghai, Shanghai |
China |
Personal and Household Products |
108.8 |
300 |
|
Subsidiary |
Wanchai |
Hong Kong |
Personal and Household Products |
|
|
|
|
Subsidiary |
Ingelheim |
Germany |
Miscellaneous Financial Services |
17,404.0 |
44,094 |
|
|
Subsidiary |
Ridgefield, CT |
United States |
Miscellaneous Financial Services |
3,167.4 |
6,493 |
|
|
Subsidiary |
Ridgefield, CT |
United States |
Biotechnology and Drugs |
|
41,500 |
|
|
Branch |
Friendswood, TX |
United States |
Personal and Household Products |
1,247.8 |
457 |
|
|
Branch |
Northbrook, IL |
United States |
Personal and Household Products |
1,181.1 |
457 |
|
|
Branch |
Downers Grove, IL |
United States |
Personal and Household Products |
36.2 |
14 |
|
|
Branch |
Reno, NV |
United States |
Biotechnology and Drugs |
7.2 |
9 |
|
|
Branch |
Atlanta, GA |
United States |
Personal and Household Products |
1,128.0 |
4 |
|
|
Affiliates |
Bedford, OH |
United States |
Biotechnology and Drugs |
207.6 |
1,000 |
|
|
Branch |
Bedford, OH |
United States |
Personal and Household Products |
1,071.3 |
1,400 |
|
|
Branch |
Bedford, OH |
United States |
Business Services |
|
5 |
|
|
Subsidiary |
Saint Joseph, MO |
United States |
Biotechnology and Drugs |
125.0 |
593 |
|
|
Branch |
Elwood, KS |
United States |
Medical Equipment and Supplies |
34.6 |
100 |
|
|
Branch |
Sioux Center, IA |
United States |
Biotechnology and Drugs |
11.6 |
50 |
|
|
Branch |
Ames, IA |
United States |
Fish and Livestock |
2.3 |
32 |
|
|
Branch |
Fort Dodge, IA |
United States |
Business Services |
7.4 |
4 |
|
|
Branch |
League City, TX |
United States |
Personal and Household Products |
1,247.8 |
457 |
|
|
Subsidiary |
Xochimilco |
Mexico |
Biotechnology and Drugs |
372.4 |
1,830 |
|
|
Subsidiary |
Sant Cugat Del Valles, Barcelona |
Spain |
Biotechnology and Drugs |
571.6 |
1,526 |
|
|
Subsidiary |
Sant Cugat Del Valles, Barcelona |
Spain |
Personal and Household Products |
185.4 |
75 |
|
|
Subsidiary |
Tokyo |
Japan |
Personal and Household Products |
1,596.5 |
1,500 |
|
|
Subsidiary |
Yamagata |
Japan |
Biotechnology and Drugs |
1.0 |
50 |
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Reims |
France |
Biotechnology and Drugs |
|
1,282 |
|
|
Boehringer Ingelheim do Brasil QuĂmica e
FarmacĂªutica Ltda |
Subsidiary |
SĂ£o Paulo, SP |
Brazil |
Biotechnology and Drugs |
342.4 |
1,107 |
|
Branch |
Itapecerica Da Serra, Sao Paulo |
Brazil |
Healthcare Facilities |
|
1,000 |
|
|
Subsidiary |
Arapongas |
Brazil |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Wien |
Austria |
Personal and Household Products |
|
1,080 |
|
|
Subsidiary |
Vienna |
Austria |
Biotechnology and Drugs |
121.1 |
1,200 |
|
|
Unit |
Vienna |
Austria |
Business Services |
1.0 |
200 |
|
|
Branch |
Bratislava |
Slovakia |
Personal and Household Products |
|
|
|
|
Subsidiary |
Bracknell |
United Kingdom |
Biotechnology and Drugs |
558.0 |
621 |
|
|
Subsidiary |
Bracknell |
United Kingdom |
Healthcare Facilities |
|
|
|
|
Subsidiary |
Bracknell |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
575 |
|
|
Subsidiary |
Buenos Aires |
Argentina |
Biotechnology and Drugs |
90.3 |
402 |
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
|
390 |
|
|
Subsidiary |
North Ryde, NSW |
Australia |
Personal and Household Products |
286.5 |
365 |
|
|
Subsidiary |
Bogota, DC |
Colombia |
Biotechnology and Drugs |
|
348 |
|
|
Subsidiary |
Elliniko |
Greece |
Biotechnology and Drugs |
299.9 |
336 |
|
|
Subsidiary |
Asker |
Norway |
Personal and Household Products |
36.9 |
300 |
|
|
Subsidiary |
Metro Manila |
Philippines |
Biotechnology and Drugs |
80.6 |
250 |
|
|
Subsidiary |
Istanbul |
Turkey |
Personal and Household Products |
|
250 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
133.8 |
232 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Fish and Livestock |
1.0 |
30 |
|
|
Subsidiary |
Randburg |
South Africa |
Miscellaneous Financial Services |
|
226 |
|
|
Subsidiary |
Randburg |
South Africa |
Personal and Household Products |
|
198 |
|
|
Subsidiary |
Caracas |
Venezuela |
Biotechnology and Drugs |
62.6 |
197 |
|
|
Subsidiary |
Bruxelles |
Belgium |
Personal and Household Products |
122.9 |
175 |
|
|
Subsidiary |
København Ă˜ |
Denmark |
Personal and Household Products |
111.3 |
156 |
|
|
Subsidiary |
Warsaw |
Poland |
Retail (Grocery) |
44.9 |
140 |
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
|
140 |
|
|
Subsidiary |
Bangkok |
Thailand |
Biotechnology and Drugs |
25.8 |
132 |
|
|
Subsidiary |
Stockholm |
Sweden |
Biotechnology and Drugs |
106.3 |
100 |
|
|
Subsidiary |
Quito |
Ecuador |
Personal and Household Products |
28.6 |
100 |
|
|
Subsidiary |
Guadalajara, Jalisco |
Mexico |
Biotechnology and Drugs |
|
100 |
|
|
Subsidiary |
Helsinki |
Finland |
Personal and Household Products |
53.7 |
86 |
|
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
23.4 |
86 |
|
|
Subsidiary |
Basel |
Switzerland |
Biotechnology and Drugs |
58.3 |
75 |
|
|
Subsidiary |
Bioggio |
Switzerland |
Biotechnology and Drugs |
166.7 |
230 |
|
|
Subsidiary |
Blanquefort |
France |
Chemical Manufacturing |
18.9 |
74 |
|
|
Subsidiary |
Manukau |
New Zealand |
Personal and Household Products |
17.0 |
22 |
|
|
Subsidiary |
Santiago |
Chile |
Personal and Household Products |
|
|
|
|
Boehringer Ingelheim International Trading
(Shanghai) Co. Ltd. |
Subsidiary |
Shanghai |
China |
Personal and Household Products |
|
|
|
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Biotechnology and Drugs |
1,578.0 |
6,000 |
|
|
Subsidiary |
Dortmund, Nordrhein-Westfalen |
Germany |
Biotechnology and Drugs |
96.9 |
420 |
|
|
Branch |
Riga |
Latvia |
Business Services |
|
|
|
|
Subsidiary |
Burlington, ON |
Canada |
Personal and Household Products |
|
700 |
|
|
Subsidiary |
Burlington, ON |
Canada |
Personal and Household Products |
|
560 |
|
|
Subsidiary |
BogotĂ¡ DC |
Colombia |
Biotechnology and Drugs |
68.6 |
298 |
|
|
Subsidiary |
Bruxelles, Bruxelles-Capitale |
Belgium |
Biotechnology and Drugs |
182.3 |
217 |
|
|
Subsidiary |
Lisboa |
Portugal |
Biotechnology and Drugs |
|
210 |
|
|
Boehringer Ingelheim Vetmedica Gesellschaft mit
beschränkter Haftung |
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Biotechnology and Drugs |
|
200 |
|
Bioscreen European Veterinary Disease Management
Center GmbH |
Subsidiary |
Hannover, Niedersachsen |
Germany |
Biotechnology and Drugs |
|
17 |
|
Subsidiary |
Bergamo, Fornovo San Giovanni |
Italy |
Chemical Manufacturing |
145.5 |
182 |
|
|
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Biotechnology and Drugs |
|
165 |
|
|
Subsidiary |
Laval, QC |
Canada |
Personal and Household Products |
278.6 |
150 |
|
|
Subsidiary |
Sant Cugat Del Valles, Barcelona |
Spain |
Business Services |
7.4 |
72 |
|
|
Subsidiary |
Sant Cugat Del Valles, Barcelona |
Spain |
Biotechnology and Drugs |
5.1 |
41 |
|
|
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Commercial Banks |
|
4 |
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
597.8 |
873 |
|
|
Subsidiary |
Milano, MI |
Italy |
Biotechnology and Drugs |
536.2 |
754 |
|
|
Subsidiary |
Alkmaar, Holland |
Netherlands |
Biotechnology and Drugs |
243.4 |
250 |
|
|
Subsidiary |
Lisboa |
Portugal |
Biotechnology and Drugs |
30.7 |
128 |
|
|
Unilfarma-Uniao Internacional de Laboratorios
Farmaceuticos, Lda. |
Subsidiary |
Lisbon |
Portugal |
Personal and Household Products |
|
210 |
|
Subsidiary |
Singapore |
Singapore |
Personal and Household Products |
25.5 |
40 |
|
|
Subsidiary |
Wan Chai, Hong Kong |
Hong Kong |
Personal and Household Products |
|
40 |
|
|
Unilfarma - UniĂ£o Internacional De LaboratĂ³rios
FarmacĂªuticos, LDA |
Subsidiary |
Lisboa, Lisboa |
Portugal |
Personal and Household Products |
84.7 |
33 |
|
Subsidiary |
Auckland, 02 |
New Zealand |
Personal and Household Products |
26.4 |
30 |
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Mexico |
Mexico |
Public Sector and Government |
408.0 |
|
|
|
Dr. Karl T h o m a e , Gesellschaft mit
beschränkter Haftung |
Subsidiary |
Biberach An Der RiĂŸ, Baden-WĂ¼rttemberg |
Germany |
Real Estate Operations |
39.0 |
|
|
Albert und Helene B o e h r i n g e r UnterstĂ¼tzungskasse
der Firma Dr. Karl Thomae, Gesells |
Subsidiary |
Biberach An Der RiĂŸ, Baden-WĂ¼rttemberg |
Germany |
Insurance (Life) |
|
|
|
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Commercial Banks |
|
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Business Services |
|
|
|
|
Subsidiary |
Cairo |
Egypt |
Personal and Household Products |
|
|
|
|
Subsidiary |
Ingelheim Am Rhein, Rheinland-Pfalz |
Germany |
Insurance (Life) |
|
|
|
|
Subsidiary |
Guadalajara |
Mexico |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Biberach An Der RiĂŸ, Baden-WĂ¼rttemberg |
Germany |
Miscellaneous Capital Goods |
|
|
Executives
Report
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
SEK |
SEK |
SEK |
|
Exchange Rate (Period Average) |
6.493691 |
7.206564 |
7.645194 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total Revenue |
106.3 |
92.5 |
86.4 |
|
Gross Profit |
4.6 |
3.3 |
4.1 |
|
Net Financial Items |
-0.2 |
-0.2 |
-0.1 |
|
Operating Income |
4.4 |
3.1 |
3.8 |
|
Income Before Tax |
4.2 |
2.9 |
3.6 |
|
Net Income |
2.9 |
2.0 |
2.5 |
|
|
|
Annual Balance Sheet |
|
Financials in: USD (mil) |
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Filed Currency |
SEK |
SEK |
SEK |
|
Exchange Rate |
6.8553 |
6.72285 |
7.1401 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total Assets |
30.0 |
29.8 |
20.3 |
|
Total Liabilities |
20.8 |
21.4 |
11.8 |
|
Total Equity |
9.2 |
8.4 |
8.6 |
|
|
|
Annual Ratios |
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
- |
- |
- |
|
Exchange Rate |
- |
- |
- |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Operating Margin |
4.11 |
3.32 |
4.35 |
|
Current Ratio |
143.51 |
137.43 |
169.13 |
|
Total debt/total equity |
30.79 |
28.08 |
42.03 |
|
Return on average equity |
42.78 |
37.27 |
45.20 |
|
|
|
Annual Growth Rates |
|
|
|
|
|
|
|
31-Dec-2010 |
31-Dec-2009 |
|
Period Length |
12 Months |
12 Months |
|
Filed Currency |
- |
- |
|
Exchange Rate |
- |
- |
|
Consolidated |
No |
No |
|
|
|
|
|
Turnover Percent Change |
3.59% |
0.97% |
|
Marginal Contribution Percent Change |
22.84% |
-22.62% |
|
Net Financial Items Percent Change |
-6.43% |
-2.85% |
|
Operating Results Percent Change |
28.10% |
-22.99% |
|
Profit/Loss Before Tax Percent Change |
29.25% |
-24.00% |
|
Profit/Loss for the Year Percent Change |
31.02% |
-24.89% |
|
Assets Percent Change |
2.69% |
37.99% |
|
Debts Percent Change |
-1.18% |
71.20% |
|
Equity Capital Percent Change |
12.60% |
-7.82% |
|
Operating Margin Percent Change |
23.80% |
-23.68% |
|
Current Ratio Percent Change |
4.42% |
-18.74% |
|
Debt/Equity Ratio Percent Change |
9.65% |
-33.19% |
|
Retun On Equity Percent Change |
14.78% |
-17.54% |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.84 |
|
|
1 |
Rs.88.16 |
|
Euro |
1 |
Rs.71.54 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.